Concert Pharmaceuticals Announces CTP-499 Late Breaking Presentation at the National Kidney Foundation 2014 Spring Clinical Meeting

Concert Pharmaceuticals Announces CTP-499 Late Breaking Presentation at the National Kidney Foundation 2014 Spring Clinical Meeting

March 19, 2014

 LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that 48 week Phase 2 clinical results of CTP-499 in patients with diabetic kidney disease will be presented at the National Kidney Foundation 2014 Spring Clinical Meeting. The meeting will take place on April 22-26, 2014 at the MGM Grand in Las Vegas, NV. The podium presentation will be made by the lead author, Dr. Bhupinder Singh, a clinical investigator for the study at Southwest Clinical Research Institute, to present the clinical results during the Late Breaking Session on Friday, April 25, 2014, 9:30 am - 11:00 am PDT. A corresponding poster presentation will also be presented at the meeting and will include data describing the effect of CTP-499 treatment on several biomarkers of fibrosis. A copy of the corresponding abstract is available on the National Kidney Foundation’s website at: http://www.kidney.org/news/meetings/clinical/abstract/index.cfm.

About CTP-499

CTP-499 is a novel, deuterium-containing oral multi-subtype selective PDE inhibitor that is being developed to slow the progression of type 2 diabetic kidney disease in patients with macroalbuminuria. In preclinical testing, CTP-499 has been shown to suppress fibrotic, inflammatory, and oxidative processes associated with the pathophysiology of diabetic kidney disease. CTP-499 is a deuterated analog of 1-(S)-5-hydroxyhexyl-3,7-dimethylxanthine, or HDX, an active metabolite of pentoxifylline. It is being developed as an additive treatment to angiotensin modulation with an ACEi or ARB, which is the current standard of care for type 2 diabetic kidney disease. A Phase 2 open-label extension study to assess treatment with CTP-499 for an additional 48 weeks of treatment is ongoing.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy. The company is developing a broad pipeline targeting CNS disorders, renal disease, inflammation and cancer.